Skip to content

Save 20% on your first AutoShip with promo code FAMILY20!Learn More

ProZinc Insulin U-40 for Dogs and Cats, 10-mL

This item requires prescription approval.

Prescription medications are currently limited to CA residents. More states coming soon!!

Original price $124.69 - Original price $124.69
Original price
$124.69
$124.69 - $124.69
Current price $124.69
Description

PROZINC is used for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs and cats with diabetes mellitus. With the largest clinical studies demonstrating efficacy and safety in both canine and feline diabetes, you can be confident in the power of PROZINC to maintain glycemic control and reduce clinical signs.

pro-zinc

Benefits
  • Can be used for initial treatment and long-term management of diabetes mellitus.
  • In a clinical study of 151 diabetic cats, most cats that received PROZINC showed improvement in 45 days.
  • 76% of cats showed improvement in excessive thirst.
  • 74% of cats showed improvement in excessive uriniation.
  • In a clinical study of 276 diabetic dogs, most dogs that received PROZINC showed improvement in 84 days.
  • 83.3% of dogs showed improvement in excessive thirst.
  • 83.8% of dogs showed improvement in excessive urination.

Consult with your veterinarian for proper dosage and course of treatment.

Warnings

Owners should be advised to observe for signs of hypoglycemia (low blood sugar). Signs may include weakness, depression, behavioral changes, muscle twitching, and anxiety.

In severe cases of hypoglycemia, seizures and coma can occur.

Hypoglycemia can be fatal if an affected animal does not receive prompt treatment.

PROZINC should not be used during episodes of hypoglycemia (low blood sugar).

Appropriate veterinary monitoring of blood glucose, adjustment of insulin dose and regimen as needed, and stabilization of diet and activity help minimize the risk of hypoglycemic episodes. The attending veterinarian should evaluate other adverse reactions on a case-by-case basis to determine if an adjustment in therapy is appropriate, or if alternative therapy should be considered.

The safety and effectiveness of PROZINC in puppies, kittens, or breeding, pregnant, and lactating animals has not been evaluated.

Precautions

For obese patients, dose calculations should be based on the patient's ideal body weight to avoid inadvertent insulin overdose.

Long term repeated injections of insulin at the same site may cause lipodystrophic reactions, which could interfere with insulin absorption.

Food and Drug Interactions
  • BETA-ADRENERGIC ANTAGONISTS (eg, atenolol, propranolol) - Can have variable effects on glycemic control and can mask the signs associated with hypoglycemia.
  • CLONIDINE - Can mask the signs associated with hypoglycemia.
  • DIGOXIN - Because insulin can reduce serum potassium levels, patients receiving concomitant digoxin therapy - especially those reveiving concurrent diuretic therapy - should be closely monitored.
  • DIURETICS (eg, furosemide, hydrochlorothiazide) - Insulin shifts extracellular potassium into the intracellular space; serum potassium concentration should be closely monitored in patients receiving concomitant diuretic therapy. Diuretics may also decrease the hypoglycemic activity of insulin (ie, increase insulin requirements).
  • RESERPINE - Can mask the signs associated with hypoglycemia.

The following drugs or drug classes may potentiate the hypoglycemic activity of insulin (ie, decrease insulin requirements).

  • ALCOHOL
  • ANABOLIC STEROIDS (eg, boldenone, stanozolol, testosterone)
  • ANGIOTENSIN II RECEPTOR BLOCKERS (eg, telmisartan)
  • ANGIOTENSIN CONVERTING ENZYME INHIBITORS (eg, benazepril, enalapril)
  • DISOPYRAMIDE
  • FENOFIBRATE
  • FLUOROQUINOLONES (eg, ciprofloxacin, enrofloxacin)
  • FLUOXETINE
  • HYPOGLYCEMICS, ORAL (eg, acarbose, glipizide, metformin)
  • MONOAMINE OXIDASE INHIBITORS (eg, amitraz, linezolid, selegiline)
  • PENTOXIFYLLINE
  • SALICYLATES (eg, aspirin, bismuth subsalicylate)
  • SOMATOSTATIN DERIVATIVES (eg, octreotide)
  • SULFONAMIDES (eg, sulfadimethoxine, sulfamethoxazole)
Human Warnings

 

Possible Side Effects

May include:

  • >Hypoglycemia (low blood sugar)
  • Hypokalemia (low potassium)
  • Insulin-induced rebound hyperglycemia
  • Insulin antagonism and resistance
  • Rapid insulin metabolism (insulin effect wears off too soon)
  • Local or allergic reactions to the "foreign" proteins

Reported in an FDA field study in dogs treated with PROZINC

  • Lethargy
  • Anorexia
  • Hypoglycemia (low blood sugar)
  • Vomiting
  • Shaking
  • Seizures
  • Ataxia (lack of muscle control or coordination)

Half of the hypoglycemic episodes did not have clinical signs. Injection site reactions occurred in 2.5% of dogs and 1.7% of cats.

Contact your veterinarian if you believe your pet is experiencing side effects.

Product Administration

Subcutaneous (under the skin) injection

Product Form

Injectable solution

Ingredients

Triamcinolone Acetonide, Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.

Storage

Store in an upright position in the refrigerator at 2-8°C (36-46°F). Protect from light. Do not freeze. Discard within 60 days (10mL vial) or 80 days (20mL vial) of first use.

Manufacturer

Boehringer Ingelheim

Prescribing Info/Brochures